Cardiovascular diseases are the leading cause of mortality in the world including Asian countries. Biomarkers that detect cardiovascular changes such as inflammation, myocardial necrosis, and cardiovascular overload are easy and non-invasive method to predict and diagnose cardiovascular diseases and widely used in clinical practice. In addition biomarkers are also used as a surrogate marker in clinical trials because it is getting more difficult to set cardiac events as an endpoint. To improve the effectiveness of biomarkers, we need to develop more sensitive and specific ones. Recently thanks to the progress of basic research, novel biomarkers are being developed. In this session, we would like to discuss the current situation how biomarkers are used in clinical practice and the development of novel biomarkers in Asian countries.
Emerging Biomarkers in Cardiovascular Diseases
|Chairperson:||Koji Maemura||(Department of Cardiovascular Medicine, Nagasaki University)|
|Youngkeun Ahn||(Chonnam National University Hospital, Korea)|